TEL: 095-819-8575
TEL (Int'l): +81-95-819-8574
 
 

HOME > 業績 Works

2019



A) English Journals

A-a

  1. Lee KC, Chen P, Maricic I, Inamine T, Hu J, Gong S, Sun JC, Dasgupta S, Lin HC, Lin YT, Loomba R, Stärkel P, Kumar V, Schnabl B. Intestinal iNKT Cells Migrate to Liver and Contribute to Hepatocyte Apoptosis During Alcoholic Liver Disease. Am J Physiol Gastrointest Liver Physiol. 2019 Feb 28. (IF: 3.293)
  2. Shiraiwa K, Matsuse M, Nakazawa Y, Ogi T, Suzuki K, Saenko V, Xu S, Umezawa K, Yamashita S, Tsukamoto K, Mitsutake N. JAK/STAT3 and NF-κB Signaling Pathways Regulate Cancer Stem-Cell Properties in Anaplastic Thyroid Cancer Cells. Thyroid. 2019 Mar 15. (IF: 7.557)
  3. Yamashita A, Inamine T, Suzuki S, Fukuda S, Unoike M, Kawafuchi Y, Machida H, Isomoto H, Nakao K, Tsukamoto K. Genetic variants of SMAD2/3/4/7 are associated with susceptibility to ulcerative colitis in a Japanese genetic background. Immunol Lett. 207:64-72, 2019. (IF: 2.436)

2018



A) English Journals

A-a

  1. Neyama H, Hamada Y, Tsukahara R, Narita M, Tsukamoto K, Ueda H. Blockade of analgesic effects following systemic administration of N-methyl-kyotorphin, NMYR and arginine in mice deficient of preproenkephalin or proopiomelanocortin gene. Peptides. 107:10-16, 2018. (IF: 2.851)
  2. Hagimori M, Chinda Y, Suga T, Yamanami K, Kato N, Inamine T, Fuchigami Y, Kawakami S. Synthesis of high functionality and quality mannose-grafted lipids to produce macrophage-targeted liposomes. Eur J Pharm Sci. 123:153-161, 2018. (IF: 3.466)

2017



A) English Journals

A-a

  1. Yang AM*, Inamine T*, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B (*Co-1st author). Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 127(7):2829-2841. (IF: 12.575)
  2. Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 8(1):837. (IF: 12.124)


A-b

2016



A) English Journals
A-a

  1. Ogawara D, Fukuda M, Ueno S, Ohue Y, Takemoto S, Mizoguchi K, Nakatomi K, Nakamura Y, Obase Y, Honda T, Tsukamoto K, Ashizawa K, Oka M, Kohno S. Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4. Support Care Cancer 24(2):615-619, 2016. (IF: 2.535)
  2. Mawatari T, Yoshida E, Higuchi N, Sato K, Inamine T, Kondo S, Fukushima K, Suyama N, Mukae H, Kohno S, Tsukamoto K. A combination polymorphism of the glutathione synthesis genes can be a predictive biomarker for anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with pulmonary tuberculosis. Journal of Lung Diseases & Treatment 2:105, 2016.
  3. Tominaga T, Tsuchiya T, Mochinaga K, Arai J, Yamasaki N, Matsumoto K, Miyazaki T, Nagasaki T, Nanashima A, Tsukamoto K, Nagayasu T. Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer. BMC Cancer 16(1):354, 2016. (IF: 3.265)
  4. Araki C, Yoshimura M, Fukumitsu Y, Ma S, Ishida T, Urabe S, Matsushima K, Honda T, Uehara R, Fukuda Y, Takeshima F, Higuchi N, Isomoto H, Nakao K, Tsukamoto K. The evidence of genetic polymorphisms of genes involved in the P2RX7 signaling pathway as predictive biomarkers for response and loss of response to infliximab against Crohn's disease. Integrative Molecular Medicine 3(6):1-15, 2016.
  5. Inamine T, Yang AM, Wang L, Lee KC, Llorente C, Schnabl B. Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. Alcohololism Clinical and Experimental Research 40(12):2604-2613, 2016. (IF: 2.829)

2015



A) English Journals

A-a

  1. Urabe S, Isomoto H, Ishida T, Maeda K, Inamine T, Kondo S, Higuchi N, Sato K, Uehara R, Yajima H, Machida H, Chen CC, Fukuda Y, Takeshima F, Nakao K, Tsukamoto K. Genetic polymorphisms of IL-17F and TRAF3IP2 could be predictive factors of the long-term effect of infliximab against Crohn’s disease. Biomed Res Int, ID 416838, 1-12, 2015. (IF: 1.5792)
  2. Kasai T, Nakamura Y, Fukuda M, Kitazaki T, Nagashima S, Takatani H, Nakano H, Nakatomi K, Ikeda T, Yamaguchi H, Tsukamoto K, Oka M, Kohno S. A phase II study of S-1 for previously untreated elderly patients with advanced non-small cell lung cancer, Chemotherapy 61(2):93-98, 2015. (IF: 1.288)


B) Japanese Journals

B-d

  • 稲嶺達夫，中村 稔，塚元和弘：CYP7A1 遺伝子多型が影響する原発性胆汁性肝硬変進行メカニズムの解明. 臨床薬理の進歩 36:91-99, 2015.

2014



A) English Journals
A-a

  1. Mochinaga K, Tsuchiya T, Nagasaki T, Arai J, Tominaga T, Yamasaki N, Matsumoto K, Miyazaki T, Nanashima A, Hayashi T, Tsukamoto K, Nagayasu T. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non-small-cell lung cancer using 5-fluorouracil. Clin Lung Cancer 15(2):136-144, 2014.(IF: 3.220)
  2. Ikeda T, Fukuda M, Nakamura Y, Kinoshita A, Senju H, Nakano H, Kitazaki T, Ogawara D, Taniguchi H, Motoshima K, Yamaguchi H, Nakatomi K, Shimada M, Nagashima S, Tsukamoto K, Kohno S. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. Cancer Chemother Phrmacol 74(3):497-502, 2014.(IF: 2.571)

2013


A) English Journals

A-a

  1. Yajima H, Isomoto H, Nishioka H, Yamaguchi N, Ohnita K, Ichikawa T, Takeshima F, Shikuwa S, Ito M, Nakao K, Tsukamoto K, Kohno S: Novel serine/threonine kinase 11 gene mutations in Peutz-Jeghers syndrome patients and endoscopic management. World J Gastrointest Endosc 5(3):102-10, 2013
  2. Inamine T, Higa S, Noguchi F, Kondo S, Omagari K, Yatsuhashi H, Tsukamoto K, Nakamura M.: Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol 48(10):1160-70, 2013 (IF: 3.788)

2012



A) English Journals

A-a

  1. Nanashima K, Mawatari T, Tahara N, Higuchi N, Nakaura A, Inamine T, Kondo S, Yanagihara K, Fukushima K, Suyama N, Kohno S, Tsukamoto K: Genetic variants in antioxidant pathway: risk factors for haptotoxicity in tuberculosis patients. Tuberculosis 92 (3): 253-259, 2012 (IF: 3.474)
  2. Arai J, Tsuchiya T, Oikawa M, Mochinaga K, Hayashi T, Yoshiura K, Tsukamoto K, Yamasaki N, Matsumoto K, Miyazaki T, Nagayasu T: Clinical and molecular analysis of synchronous double lung cancers. Lung Cancer 77 (2): 281-287, 2012 (IF: 3.434)
  3. Takatani H, Nakamura Y, Nagashima S, Soda H, Kinoshita A, Fukuda M, Fukuda M, Soejima Y, Kasai T, Nakatomi K, Iida T, Oka M, Tsukamoto K, Kohno S: Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer. Clin Lung Cancer 13 (5): 347-351, 2012 (IF: 2.944)
  4. Ikeda T, Nakamura Y, Yamaguchi H, Tomonaga N, Doi S, Nakatomi K, Iida T, Motoshima K, Mizoguchi K, Nagayasu T, Tsukamoto K, Kohno S: Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 13 (5): 369-374, 2012 (IF: 2.944)
  5. Fukuda M, Nakamura Y, Kinoshita A, Soejima Y, Yamaguchi H, Ikeda T, Izumikawa K, Takatani H, Fukuda M, Soda H, Hayashi N, Tsukamoto K, Oka M, Kohno S: Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease smal cell lung cancer. Cancer Chemother Pharmacol 70 (5): 645-651, 2012 (IF: 2.833)

2011 and before



2011
A) English Journals

A-a

  1. Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda M, Fukuda M, Takatani H, Nagashima S, Soejima Y, Kasai T, Nakatomi K, Masuda N, Tsukamoto K, Kohno S. Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. J Thorac Oncol 6(1):121-127, 2011. (IF: 4.040)
  2. Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, Kohno S. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 67(2):331-338, 2011. (IF: 2.759)
  3. Fukae A, Ikeda S, Inoue M, Tachibana T, Inamine T, Kondo S, Miyahara Y, Maemura K, Kohno S, Tsukamoto K. The evidence of polymorphisms of the liver X receptor gene as a DNA-based biomarker for susceptibility to coronary artery disease in a Japanese population. Acta Medica Nagasakiensia 55(2):69-76, 2011.
  4. Inamine T, Nakamura M, Kawauchi A, Shirakawa Y, Hashiguchi H, Aiba Y, Taketomi A, Shirabe K, Nakamuta M, Hayashi S, Saoshiro T, Komori A, Kondo S, Omagari K, Maehara Y, Ishibashi H, Tsukamoto K. A polymorphism in the integrin αV subunit gene affects the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterology 46(5):676-686, 2011. (IF: 3.610)
  5. Aiba Y, Nakamura M, Joshita S, Inamine T, Komori A, Yoshizawa K, Umemura T, Horie H, Migita K, Yatsuhashi H, Nakamuta M, Fukushima N, Saoshiro T, Hayashi S, Kouno H, Ota H, Muro T, Watanabe Y, Nakamura Y, Komeda T, Shimada M, Masaki N, Komatsu T, Yagura M, Sugi K, Koga M, Tsukamoto K, Tanaka E, Ishibashi H. Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients. J Gastroenterology 46(10):1203-1212, 2011. (IF: 3.610)
  6. Miyazaki T, Izumikawa K, Yamauchi S, Inamine T, Nagayoshi Y, Saijo T, Seki M, Kakeya H, Yamamoto Y, Yanagihara K, Miyazaki Y, Yasuoka A, Kohno S. The glycosylphosphatidylinositol-linked aspartyl protease Yps1 is transcriptionally regulated by the calcineurin-Crz1 and Slt2 MAPK pathways in Candida glabrata. FEMS Yeast Res 11(5):449-456, 2011. (IF: 2.279)


B) Japanese Journals

B-a

  1. 中嶋弥穂子，荒木良介，中里未央，前田隆浩，白濱 敏，八坂貴宏，神田哲郎，大園恵幸，青柳 潔，塚元和弘，畑山 範:長崎県五島列島での医薬共修による地域医療実習の実践.医療薬学 37(8):457-465, 2011.
  2. 佐道紳一，辻 泰弘，平木洋一，塚元和弘:用量反応曲線を用いた塩酸バンコマイシンの腎機能障害発現の予測. 日本病院薬剤師雑誌 47(10):1294-1296, 2011.


2010
A) English Journals

A-a

  1. Sadoh S, Tsuji Y, Tsukamoto K: Correlation of pharmacokinetic parameters with serum vancomycin concentration in elderly patients with malignancies. Yakugaku Zasshi 130(1):69-73, 2010.
  2. Nakamura Y, Sano K, Soda H, Takatani H, Fukuda M, Nagashima S, Hayashi T, Oka M, Tsukamoto K, Kohno S. Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol 5(9):1404-1409, 2010. (IF: 4.547)
  3. Matsuzawa N, Kondo S, Shimozato K, Nagao T, Nakano M, Tsuda M, Hirano A, Niikawa N, Yoshiura K. Two missense mutations of the IRF6 gene in two Japanese families with popliteal pterygium syndrome. Am J Med Genet A. 152A(9):2262-2267,2010. (IF:2.404)
  4. Miyazaki T, Yamauchi S, Inamine T, Nagayoshi Y, Saijo T, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Yanagihara K, Miyazaki Y, Kohno S. Roles of calcineurin and Crz1 in antifungal susceptibility and virulence of Candida glabrata. Antimicrob Agents Chemother 54(4):1639-1643, 2010. (IF: 4.802)
  5. Miyazaki T, Inamine T, Yamauchi S, Nagayoshi Y, Saijo T, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Yanagihara K, Miyazaki Y, Kohno S. Role of the Slt2 mitogen-activated protein kinase pathway in cell wall integrity and virulence in Candida glabrata. FEMS Yeast Res 10(3):343-352, 2010. (IF: 1.785)


B) Japanese Journals

B-b

  • 塚元和弘，大曲勝久，中村 稔:胆汁酸の排泄に関与するABC トランスポーター多型と原発性胆汁性肝硬変の重症化との関連. 臨床薬理の進歩 31:73-86, 2010.


2009
A) English Journals

A-a

  1. Miyazaki K, Mapendano CK, Fuchigami T, Kondo S, Ohta T, Kinoshita A, Tsukamoto K, Yoshiura K, Niikawa N, Kishino T: Developmentally dynamic changes of DNA methylation in the mouse Snurf/Snrpn gene. Gene 432(1-2):97-101, 2009 (IF: 2.578)
  2. Narumi Y, Isomoto H, Shiota M, Sato K, Kondo S, Machida H, Yanagihara K, Mizuta Y, Kohno S, Tsukamoto K: Polymorphisms of PTPN11 coding SHP-2 as biomarkers for ulcerative colitis susceptibility in the Japanese populaiton. J Clin Immunol 29(3):303-310, 2009 (IF: 3.248)
  3. Fukuda M, Nakamura Y, Kasai T, Nagashima S, Nakatomi K, Doi S, Nakano H, Takatani H, Fukuda M, Kinoshita A, Soda H, Tsukamoto K, Oka M, Kohno S; Nagasaki Thoracic Oncology Group. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. J Thorac Oncol 4(6):741-745, 2009 (IF: 3.508)
  4. Yanagihara K, Kihara R, Araki N, Morinaga Y, Seki M, Izumikawa K, Kakeya H, Yamamoto Y, Yamada Y, Kohno S, Tsukamoto K, Kamihira S: Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive methicillin-resistant Staphylococcus aureus (MRSA) in a mouse model of hematogenous pulmonary infection. Int J Antimicrob Agents 34(5):477-481, 2009 (IF: 3.067)
  5. Sato K, Shiota M, Fukuda S, Iwamoto E, Machida H, Inamine T, Kondo S, Yanagihara K, Isomoto H, Mizuta Y, Kohno S, Tsukamoto K: Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn’s disease in the Japanese population. J Clin Immunol 29(6):815-825, 2009 (IF: 3.248)
  6. de Lima RL, Hoper SA, Ghassibe M, Cooper ME, Rorick NK, Kondo S, Katz L, Marazita ML, Compton J, Bale S, Hehr U, Dixon MJ, Daack-Hirsch S, Boute O, Bayet B, Revencu N, Verellen-Dumoulin C, Vikkula M, Richieri-Costa A, Moretti-Ferreira D, Murray JC, Schutte BC: Prevalence and nonrandom distribution of exonic mutations in interferon regulatory factor 6 in 307 families with Van der Woude syndrome and 37 families with popliteal pterygium syndrome. Genet Med 11(4):241-247, 2009 (IF: 3.716)
  7. Super Science High School Consortium: Japanese map of the earwax gene frequency: a nationwide collaborative study by Super Science High School Consortium. J Hum Genet 54(9):499-503, 2009 (IF: 2.431)
  8. Oshima K, Fujii H, Eguchi K, Otani M, Matsuo T, Kondo S, Yoshiura K, Yamamoto T: A further insight into the origin of human T-lymphotropic virus type 1 (HTLV-1) in Japan, based on the genotyping of ABCC11. Tropical Medicine and Health 37(3):121-123, 2009


B) Japanese Journals

B-b

  1. 塚元和弘: 抗がん剤への耐性獲得とくすりの効かない現象：排出ポンプ. 医薬ジャーナル 45(8):125-130, 2009
  2. 大石裕樹，中村 稔，塚元和弘: MDR3 遺伝子多型とPBC. 肝胆膵 59(6):1207-1216,




2008
A) English Journals

A-a

  1. Chuan CC, Isomoto H, Narumi Y, Sato K, Oishi Y, Kobayashi T, Yanagihara K, Mizuta Y, Kohno S, Tsukamoto K: Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population. Clin Immunol 126 (2): 165-171, 2008 (IF: 3.551)
  2. Nakano H, Nakamura Y, Soda H, Kamikatahira M, Uchida K, Takasu M, Kitazaki T, Yamaguchi H, Nakatomi K, Yanagihara K, Kohno S, Tsukamoto K: Methylation status of breast cancer resistance protein detected by methylation-specific PCR is inversely correlated with its expression in drug-resistant lung cancer cells. Cancer 112 (5): 1122-1130, 2008 (IF: 4.632)
  3. Nakano H, Soda H, Takasu M, Tomonaga N, Yamaguchi H, Nakatomi K, Fujino S, Hayashi T, Nakamura Y, Tsukamoto K, Kohno S: Heterogeity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung node. Lung cancer 60 (1): 136-140, 2008 (IF: 3.455)
  4. Soda H, Nakamura Y, Nakatomi K, Tomonaga N, Yamaguchi H, Nakano H, Nagashima S, Anami M, Hayashi T, Tsukamoto K, Kohno S: Stepwise progression from ground-glass opacity towards invasive adenocarcinoma: long-term follow-up of radiological findings. Lung Cancer 60 (2): 298-301, 2008 (IF: 3.455)
  5. Kihara R, Yanagihara K, Morinaga Y, Araki N, Nakamura S, Seki M, Izumikawa K, Kakeya H, Yamamoto Y, Tsukamoto K, Kamihira S, Kohno S: Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 52 (6): 2163-2168, 2008 (IF: 4.390)
  6. Ohishi Y, Nakamura M, Iio N, Higa S, Inayoshi M, Aiba Y, Komori A, Omagari K, Ishibashi H, Tsukamoto K: Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology 48 (3): 853-862, 2008 (IF: 10.734)
  7. Nakashima M, Tsuda M, Kinoshita A, Kishino T, Kondo S, Shimokawa O, Niikawa N, Yoshiura K: Precision of high-throughput single-nucleotide polymorphism genotyping with fingernail DNA: comparison with blood DNA.Clin Chem 54 (10): 1746-1748, 2008 (IF: 4.803)
  8. Nakashima M, Nakano M, Hirano A, Kishino T, Kondo S, Miwa N, Niikawa N, Yoshiura K: Genome-wide linkage analysis and mutation analysis of hereditary congenital blepharoptosis in a Japanese family.J Hum Genet 53 (1): 34-41, 2008 (IF: 2.275)


B) Japanese Journals

B-a

  1. 樋口則英，稲嶺達夫，兒玉幸修，森田光貴，佐藤加代子，塚元和弘，境 徹也，澄川耕二，清水和宏，佐藤伸一，藤 秀人，北原隆志，佐々木 均: 院内製剤20%塩化アルミニウムエタノール（汗水）の効果および副作用の検討.日本病院薬剤師会雑誌 44 (2): 269-272, 2008
  2. 佐道紳一，辻 泰弘，玉嶋史朗，神村英利，塚元和弘: 高齢者におけるテイコプラニンの臨床効果に影響を及ぼす因子－トラフ血中濃度と血清アルブミン値に関する検討－. 日本病院薬剤師会雑誌 44 (3): 401-403, 2008

B-b

  • 樋口則英，潮田瑞穂，森田光貴，佐藤加代子，中川博雄，江頭かの子，塚元和弘，藤 秀人，北原隆志，佐々木均:総合ビタミン配合型高カロリー輸液製剤の適正使用状況調査. 新薬と臨床 57(9):118-124, 2008 (Sep.)


2007
A) English Journals

A-a

  1. Yanagihara K, Kuroki M, Higuchi N, Ohno H, Higashiyama Y, Miyazaki Y, Hirakata Y, Mukae H, Tomono K, Mizuta Y, Kadota J, Tsukamoto K, Kohno S. Telithromycin inhibits the number of viable bacteria but not lymphocyte accumulation in a murine model of chronic respiratory infection. Chemotherapy. 53:10-13, 2007. (IF: 1.511)
  2. Yahagihara K, Fukuda Y, Seki M, Izumikawa K, Miyazaki Y, Hirakata Y, Tsukamoto K, Yamada Y, Kamihira S, Kohno S. Effects of specific neutrophil elastase inhibitor, sivelestar sodium hydrate, in murine model of severe Peumococcal peumonia. Exp Lung Res. 33:71-80, 2007. (IF: 1.427)
  3. Fukuda M, Soda H, Fukuda M, Kinoshita A, Nakamura Y, Nagashima S, Takatani H, Tsukamoto K, Kohno S, Oka M. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutioal phase 2 study. Cancer. 110:606-613, 2007. (IF: 4.582)
  4. Nakano H, Soda H, Takasu M, Tomonaga N, Yamaguchi H, Nakatomi K, Fujino S, Hayashi T, Nakamura Y, Tsukamoto K, Kohno S. Heterogeity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung node. Lung cancer, 2007 Sep 21; Epub ahead of print. (IF: 3.554)
  5. Soda H, Nakamura Y, Nakatomi K, Tomonaga N, Yamaguchi H, Nakano H, Nagashima S, Anami M, Hayashi T, Tsukamoto K, Kohno S. Stepwise progression from ground-glass opacity towards invasive adenocarcinoma: long-term follow-up of radiological findings. Lung Cancer, 2007 Oct 8; Epub ahead of print. (IF: 3.554)
  6. Nakano H, Soda H, Nakamura Y, Uchida K, Takasu M, Nakatomi K, Izumikawa K, Hayashi T, Nagayasu T, Tsukamoto K, Kohno S. Different epidermal growth factor receptor gene mutations in a patient with two synchronous lung cancers. Clin Lung Cancer. 8(9):562-564, 2007.
  7. Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, Miyazaki Y, Kobayashi T, Yoshiura K, Niikawa N, Wen C-Y, Isomoto H, Shikuwa S, Mizuta Y, Kohno S, Tsukamoto K. A haplotype, NAT2*6A, of the N-acetyltransferase 2 gene is an important biomarker for a risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol. 13:6003-6008, 2007. (IF: 3.318)


B) Japanese Journals

B-a

  1. 樋口則英，稲岡奈津子，田原尚子，森田光貴，濱本知之，北原隆志，土井健志，塚元和弘，藤 秀人，一川暢宏，佐々木 均：統合失調症患者における抗精神病薬処方中のパーキンソン病治療薬併用率に関する検討．日本病院薬剤師会雑誌 43: 353-356, 2007.
  2. 樋口則英，江頭かの子，森田光貴，鳴海由希子，西川太恵，柳原克紀，塚元和弘，龍 恵美，北原隆志，児玉幸修，大山 要，一川暢宏，佐々木 均：同種造血幹細胞におけるシクロスポリン血中濃度と移植片対宿主病抑制効果についての検討．日本病院薬剤師会雑誌 43: 946-949, 2007.


2006
A) English Journals

A-a

  1. Yanagihara K, Tashiro M, Fukuda Y, Ohno H, Higashiyama Y, Miyazaki Y, Hirakata Y, Tomono K, Mizuta Y, Tsukamoto K, Kohno S: Effects of short interfering RNA against methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo. J Antimicrob Chemother 57(1):122-126, 2006. (IF: 3.886)
  2. Fukuda Y, Yanagihara K, Ohno H, Higashiyama Y, Miyazaki Y, Tsukamoto K, Hirakata Y, Tomono K, Mizuta Y, Tashiro T, Kohno S: In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. Antimicrob Agents Chemother 50(1):121-125, 2006. (IF: 4.379)
  3. Fukuda Y, Yanagihara K, Higashiyama Y, Miyazaki Y, Hirakata Y, Mukae H, Tomono K, Mizuta Y, Tsukamoto K, Kohno S: Effects of macrolides against pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 27(5):1020-1025, 2006. (IF: 3.947)
  4. Nakatomi K, Soda H, Kitazaki T, Nakano H, Uchida K, Urabe S, Nakamura Y, Hayashi T, Tsukamoto K, Kohno S: Long-term survival in three patients with metastatic non-small cell lungcancer treated with gefitinib. Lung Cancer 52(2):253-255, 2006. (IF: 3.172)
  5. Yamaguchi H, Soda H, Kitazaki T, Tsukamoto K, Hayashi T, Kohno S: Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 52(2):261-262, 2006. (IF: 3.172)
  6. Suzuki K, Morimoto M, Yamauchi M, Yoshida H, Kodama S, Tsukamoto K, Watanabe M: Visualization of centrosomes by antibodies recognizing phosphorylated ATM at serine 1981 is independent of DNA damage. Cell Cycle 5(9):1008-1009, 2006.
  7. Yanagihara K, Seki M, Izumikawa K, Higashiyama Y, Miyazaki Y, Hirakata Y, Tomono K, Mizuta Y, Tsukamoto K, Kohno S: Petency of DX-619, a novel des-F(6)-quinolone, in haematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Int J Antimicrob Agents 28(3):212-216, 2006. (IF: 2.428)
  8. Yanagihara K, Fukuda Y, Seki M, Izumikawa K, Higashiyama Y, Miyazaki Y, Hirakata Y, Tomono K, Mizuta Y, Tsukamoto K, Kohno S: Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elder patients with community-acquired pneumonia. Intern Med 45(17):995-999, 2006. (IF: 0.643)
  9. Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S: BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 58(5):594-600, 2006. (IF: 2.235)


B) Japanese Journals

B-a

  1. 樋口則英，内田華奈子，柳原克紀，塚元和弘，北原隆志，一川暢宏，佐々木 均：テイコプラニン投与中の肝機能検査異常変動の調査解析．日本病院薬剤師会雑誌42(10): 1321-1324, 2006.

B-b

  1. 小林 奨，宮崎義継：ボリコナゾール(ブイフェンド錠)．クリニカルプラクティス25:40-41, 2006.
  2. 小林 奨，宮崎義継：透析患者における難治性感染症－最新の診断と治療 6)深在性真菌症 カンジダ症，アスペルギルス症，クリプトコッカス症の診断と治療．臨床透析22: 195-201, 2006.

B-c

  • 小林 奨：クリプトコックスの病原性は？．（河野 茂(編)：深在性真菌症Q&A，医薬ジャーナル社，大阪，pp. 42-43所収）2006.
ページの先頭へ